Velnacrine in Alzheimer’s Disease
- 10 Downloads
Velnacrine is an hydroxylated derivative of the acetylcholinesterase inhibitor tacrine. The ability of velnacrine to increase cholinergic neurotransmission in vitro provides the rationale for its investigation as a potential treatment in patients with Alzheimer’s disease, who are known to have reduced acetylcholine levels in the central nervous system. Single doses of velnacrine (100 or 150mg) attenuated cognitive impairment induced by central cholinergic blockade in healthy volunteers, and memory improved significantly in a small number of patients with Alzheimer’s disease administered a 75mg dose.
Evidence of efficacy for velnacrine is limited to results of briefly reported placebo-controlled studies. When administered in dosages of up to 225 mg/day for 6 weeks, velnacrine appeared to confer modest benefit in about one-third of 423 patients with Alzheimer’s disease enrolled in a US dose-finding trial. Velnacrine 150 mg/day for 10 days was also considered superior to placebo in a small European trial involving 35 patients, notably in its effects on language, praxis and memory. Fuller results are anticipated from a 6-month investigation demonstrating efficacy for velnacrine 150 or 225 mg/day at 12-week interim analysis. Of interest is the finding from this trial that caregiver time assessed at 24 weeks was shorter for velnacrine compared with placebo recipients.
The development of elevated plasma hepatic enzyme levels leading to treatment discontinuation in 27% of participants in the US trial, combined with the appearance of neutropenia in a few patients, has cast doubt over the tolerability profile of velnacrine. Ongoing investigations are endeavouring to identify the mechanism of the hepatotoxic effect, to establish whether a dose-response relationship exists, and to define possible subpopulations that may respond to velnacrine and those who may be at particular risk of developing hepatotoxicity. Other reported adverse events severe enough to cause treatment withdrawal have included rash, nausea, diarrhoea, headache and dizziness/fainting.
In summary, questions surrounding the tolerability and efficacy of velnacrine must be resolved before its early promise as a treatment in Alzheimer’s disease can be realised. Nonetheless, given the limited therapeutic options presently, available, the drug may yet prove to be of value in at least some patients with Alzheimer’s disease.
KeywordsAdis International Limited Tacrine Caregiver Time Velnacrine Elevated Hepatic Enzyme Level
Unable to display preview. Download preview PDF.
- 1.Jaen JC, Davis RE. Cholinergic therapies for Alzheimer’s disease: acetylcholinesterase inhibitors of current clinical interest. Curr Opin Invest Drugs 1993; 2: 363–77Google Scholar
- 2.Winblad B, Messamore E, O’Neill C, et al. Biochemical pathology and treatment strategies in Alzheimer’s disease: emphasis on the cholinergic system. Acta Neurol Scand 1993; Suppl.149: 4–6Google Scholar
- 9.Wagstaff AI, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in Alzheimer’s disease. Drugs & amp;Aging 1994; 4, In pressGoogle Scholar
- 10.Siegfried KR. Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand 1993; Suppl.149: 26–8Google Scholar
- 17.Puri SK, Hsu R, Ho I, et al. Single-dose safety, tolerance, and pharmacokinetics of HP 029 in elderly men: a potential Alzheimer agent. Curr Ther Res 1988; 44: 766–80Google Scholar
- 21.McNally WP, DeHart P, Pool W, et al. A comparison of in vivo distribution of radioactivity in rat brain following oral administration of tacrine or its I-hydroxymetabolite [abstract). Soc Neurosci Abst 1991; 17: 701Google Scholar
- 22.Pool WF, Bjorge SM, Windsor B, et al. Comparison of brain to plasma metabolic distributions of tacrine and I-hydroxytacrine in rat [abstract). Soc Neurosci Abst 1991; 17: 700Google Scholar
- 23.Turcan RG, Hillbeck D, Hartley TE, et al. Disposition of [14C]velnacrine maleate in rats, dogs and humans. Drug Metab Dis 1993; 21: 1037–47Google Scholar
- 26.Siegfried K. A placebo-controlled crossover study of velnacrine in patients with Alzheimer’s disease [abstract). Neurology 1992; 42 Suppl.3: 141Google Scholar
- 27.Anonymous. Scrip 1992a; No. 1769 Nov 10: 22–3Google Scholar
- 28.Anonymous. F-D-C Reports 1992b; 54 Nov 09: 5–7Google Scholar
- 31.Horn R, Kasper S, Eichert V, et al. Mapping of EEG and P300 in patients with dementia of Alzheimer type and treatment with velnacrine (HP-029) [abstract). Pharmacopsychiatry 1992; 25: 105Google Scholar
- 32.Hardiman S, Miller K, Murphy M. Clinical trials with velnacrine: (PROPP) The physician reference of predicted probabilities—a statistical model for the estimation ofhepatoxicity risk with velnacrine maleate. Acta Neurol Scand 1993; Suppl. 149: 46–52Google Scholar
- 35.Cutler NR, Sramek JJ, Murphy MF, et al. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer’s disease. Ann Pharmacotherapy 1992; 26: 1118–22Google Scholar
- 37.Henderson AS. Alzheimer’s disease in its epidemiological context. Acta Neurol Scand 1993; Suppl.149: 1–3Google Scholar
- 38.Scarle MA. Velnacrine: a tacrine analogue for senile dementia. P & T 1992; 17: 1786–8Google Scholar
- 40.Moos WH, Hershenson FM. Potential therapeutic strategies for senile cognitive disorders. Drug News Perspect 1989; 2: 397–409Google Scholar
- 44.Cutler NR, Sramek JJ, Seifert RD, et al. The target population in Phase I clinical trials of acetylcholinesterase inhibitors in dementia: the role of the ‘bridging study’. In: Corain B, et al., editors. Alzheimer’s disease: advances in clinical and basic research. John Wiley & Sons Ltd, 1993: 559–62Google Scholar